Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression

M. Petráš, R. Máčalík, D. Janovská, AM. Čelko, J. Dáňová, E. Selinger, J. Doleček, S. Neradová, M. Franklová, P. Dlouhý, J. Rosina, IK. Lesná

. 2022 ; 20 (1) : 461. [pub] 20221125

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu metaanalýza, časopisecké články, přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032586

BACKGROUND: Observational studies made it possible to assess the impact of risk factors on the long-term effectiveness of mRNA and adenoviral vector (AdV) vaccines against COVID-19. METHODS: A computerized literature search was undertaken using the MEDLINE, EMBASE, and MedRxiv databases to identify eligible studies, with no language restrictions, published up to 28 February 2022. Eligible were observational studies assessing vaccine effectiveness (VE) by disease severity with reference groups of unvaccinated participants or participants immunized with one, two, or three vaccine doses. Our study was carried out in compliance with the PRISMA and MOOSE guidelines. The risk of study bias was identified using the Newcastle-Ottawa Quality Assessment Scale. The GRADE guidelines were applied to assess the strength of evidence for the primary outcome. The synthesis was conducted using a meta-analysis and meta-regression. RESULTS: Out of a total of 14,155 publications, 290 studies were included. Early VE of full vaccination against COVID-19 of any symptomatology and severity decreased from 96% (95% CI, 95-96%) for mRNA and from 86% (95% CI, 83-89%) for AdV vaccines to 67% for both vaccine types in the last 2 months of 2021. A similar 1-year decline from 98 to 86% was found for severe COVID-19 after full immunization with mRNA, but not with AdV vaccines providing persistent 82-87% effectiveness. Variant-reduced VE was only associated with Omicron regardless of disease severity, vaccine type, or vaccination completeness. The level of protection was reduced in participants aged >65 years, with a comorbidity or those in long-term care or residential homes independently of the number of doses received. The booster effect of the third mRNA dose was unclear because incompletely restored effectiveness, regardless of disease severity, declined within a short-term interval of 4 months. CONCLUSIONS: Full vaccination provided an early high, yet waning level of protection against COVID-19 of any severity with a strong impact on the high-risk population. Moreover, the potential risk of new antigenically distinct variants should not be underestimated, and any future immunization strategy should include variant-updated vaccines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032586
003      
CZ-PrNML
005      
20250611113830.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12916-022-02663-z $2 doi
035    __
$a (PubMed)36434597
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Petráš, Marek $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Prague, Czech Republic. marek.petras@lf3.cuni.cz $1 https://orcid.org/0000000329131736
245    10
$a Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression / $c M. Petráš, R. Máčalík, D. Janovská, AM. Čelko, J. Dáňová, E. Selinger, J. Doleček, S. Neradová, M. Franklová, P. Dlouhý, J. Rosina, IK. Lesná
520    9_
$a BACKGROUND: Observational studies made it possible to assess the impact of risk factors on the long-term effectiveness of mRNA and adenoviral vector (AdV) vaccines against COVID-19. METHODS: A computerized literature search was undertaken using the MEDLINE, EMBASE, and MedRxiv databases to identify eligible studies, with no language restrictions, published up to 28 February 2022. Eligible were observational studies assessing vaccine effectiveness (VE) by disease severity with reference groups of unvaccinated participants or participants immunized with one, two, or three vaccine doses. Our study was carried out in compliance with the PRISMA and MOOSE guidelines. The risk of study bias was identified using the Newcastle-Ottawa Quality Assessment Scale. The GRADE guidelines were applied to assess the strength of evidence for the primary outcome. The synthesis was conducted using a meta-analysis and meta-regression. RESULTS: Out of a total of 14,155 publications, 290 studies were included. Early VE of full vaccination against COVID-19 of any symptomatology and severity decreased from 96% (95% CI, 95-96%) for mRNA and from 86% (95% CI, 83-89%) for AdV vaccines to 67% for both vaccine types in the last 2 months of 2021. A similar 1-year decline from 98 to 86% was found for severe COVID-19 after full immunization with mRNA, but not with AdV vaccines providing persistent 82-87% effectiveness. Variant-reduced VE was only associated with Omicron regardless of disease severity, vaccine type, or vaccination completeness. The level of protection was reduced in participants aged >65 years, with a comorbidity or those in long-term care or residential homes independently of the number of doses received. The booster effect of the third mRNA dose was unclear because incompletely restored effectiveness, regardless of disease severity, declined within a short-term interval of 4 months. CONCLUSIONS: Full vaccination provided an early high, yet waning level of protection against COVID-19 of any severity with a strong impact on the high-risk population. Moreover, the potential risk of new antigenically distinct variants should not be underestimated, and any future immunization strategy should include variant-updated vaccines.
650    _2
$a lidé $7 D006801
650    12
$a vakcíny proti COVID-19 $7 D000086663
650    12
$a COVID-19 $x prevence a kontrola $7 D000086382
650    _2
$a účinnost vakcíny $7 D000087507
650    _2
$a rizikové faktory $7 D012307
650    _2
$a messenger RNA $7 D012333
655    _2
$a metaanalýza $7 D017418
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Máčalík, Roman $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Prague, Czech Republic
700    1_
$a Janovská, Daniela $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Prague, Czech Republic
700    1_
$a Čelko, Alexander M $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Prague, Czech Republic
700    1_
$a Dáňová, Jana $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Prague, Czech Republic
700    1_
$a Selinger, Eliška $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Prague, Czech Republic $u Centre for Public Health Promotion, National Institute of Public Health, 100 00, Prague, Czech Republic
700    1_
$a Doleček, Jonáš $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Prague, Czech Republic
700    1_
$a Neradová, Sylva $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Prague, Czech Republic
700    1_
$a Franklová, Martina $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruská 87, 100 00, Prague, Czech Republic
700    1_
$a Dlouhý, Pavel $u Department of Hygiene, Third Faculty of Medicine, Charles University, 100 00, Prague, Czech Republic
700    1_
$a Rosina, Jozef $u Department of Medical Biophysics and Informatics, Third Faculty of Medicine, Charles University, 100 00, Prague, Czech Republic $u Department of Health Care and Population Protection, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01, Kladno, Czech Republic
700    1_
$a Lesná, Ivana K. $u Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21, Prague, Czech Republic $u Department of Anesthesia and Intensive Medicine, First Faculty of Medicine, Charles University and University Military Hospital, 100 00, Prague, Czech Republic $7 xx0112415
773    0_
$w MED00008190 $t BMC medicine $x 1741-7015 $g Roč. 20, č. 1 (2022), s. 461
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36434597 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20250611113822 $b ABA008
999    __
$a ok $b bmc $g 1891386 $s 1183921
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 20 $c 1 $d 461 $e 20221125 $i 1741-7015 $m BMC medicine $n BMC Med $x MED00008190
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace